Logo image of MRNA

MODERNA INC (MRNA) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:MRNA - US60770K1079 - Common Stock

41.83 USD
+2.47 (+6.28%)
Last: 1/16/2026, 8:00:01 PM
41.82 USD
-0.01 (-0.02%)
After Hours: 1/16/2026, 8:00:01 PM
Fundamental Rating

3

Taking everything into account, MRNA scores 3 out of 10 in our fundamental rating. MRNA was compared to 528 industry peers in the Biotechnology industry. MRNA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. MRNA is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

  • In the past year MRNA has reported negative net income.
  • In the past year MRNA has reported a negative cash flow from operations.
  • In multiple years MRNA reported negative net income over the last 5 years.
  • The reported operating cash flow has been mixed in the past 5 years: MRNA reported negative operating cash flow in multiple years.
MRNA Yearly Net Income VS EBIT VS OCF VS FCFMRNA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5B 10B

1.2 Ratios

  • With a decent Return On Assets value of -25.68%, MRNA is doing good in the industry, outperforming 71.21% of the companies in the same industry.
  • The Return On Equity of MRNA (-33.40%) is better than 73.48% of its industry peers.
Industry RankSector Rank
ROA -25.68%
ROE -33.4%
ROIC N/A
ROA(3y)-6.14%
ROA(5y)4.17%
ROE(3y)-7.66%
ROE(5y)6.83%
ROIC(3y)N/A
ROIC(5y)N/A
MRNA Yearly ROA, ROE, ROICMRNA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 60 80

1.3 Margins

  • MRNA's Gross Margin of 63.49% is fine compared to the rest of the industry. MRNA outperforms 79.17% of its industry peers.
  • MRNA's Gross Margin has declined in the last couple of years.
  • The Profit Margin and Operating Margin are not available for MRNA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 63.49%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-6.55%
GM growth 5YN/A
MRNA Yearly Profit, Operating, Gross MarginsMRNA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800

More info and screens

5

2. Health

2.1 Basic Checks

  • MRNA does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, MRNA has more shares outstanding
  • Compared to 5 years ago, MRNA has more shares outstanding
  • MRNA has a better debt/assets ratio than last year.
MRNA Yearly Shares OutstandingMRNA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M
MRNA Yearly Total Debt VS Total AssetsMRNA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B 20B 25B

2.2 Solvency

  • An Altman-Z score of 4.04 indicates that MRNA is not in any danger for bankruptcy at the moment.
  • MRNA's Altman-Z score of 4.04 is fine compared to the rest of the industry. MRNA outperforms 71.40% of its industry peers.
  • A Debt/Equity ratio of 0.00 indicates that MRNA is not too dependend on debt financing.
  • MRNA has a Debt to Equity ratio (0.00) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 4.04
ROIC/WACCN/A
WACC8.82%
MRNA Yearly LT Debt VS Equity VS FCFMRNA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5B 10B 15B

2.3 Liquidity

  • MRNA has a Current Ratio of 3.93. This indicates that MRNA is financially healthy and has no problem in meeting its short term obligations.
  • With a Current ratio value of 3.93, MRNA perfoms like the industry average, outperforming 47.35% of the companies in the same industry.
  • A Quick Ratio of 3.73 indicates that MRNA has no problem at all paying its short term obligations.
  • With a Quick ratio value of 3.73, MRNA perfoms like the industry average, outperforming 47.16% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.93
Quick Ratio 3.73
MRNA Yearly Current Assets VS Current LiabilitesMRNA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B

More info and screens

5

3. Growth

3.1 Past

  • MRNA shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -38.66%.
  • The Revenue for MRNA has decreased by -56.07% in the past year. This is quite bad
  • MRNA shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 122.01% yearly.
EPS 1Y (TTM)-38.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1800%
Revenue 1Y (TTM)-56.07%
Revenue growth 3Y-44.04%
Revenue growth 5Y122.01%
Sales Q2Q%-45.44%

3.2 Future

  • The Earnings Per Share is expected to grow by 16.39% on average over the next years. This is quite good.
  • MRNA is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 10.92% yearly.
EPS Next Y11.47%
EPS Next 2Y11.1%
EPS Next 3Y13.46%
EPS Next 5Y16.39%
Revenue Next Year-40.97%
Revenue Next 2Y-22.34%
Revenue Next 3Y-11.19%
Revenue Next 5Y10.92%

3.3 Evolution

  • Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
MRNA Yearly Revenue VS EstimatesMRNA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 5B 10B 15B
MRNA Yearly EPS VS EstimatesMRNA Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 10 -10 20

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

  • MRNA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MRNA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MRNA Price Earnings VS Forward Price EarningsMRNA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MRNA Per share dataMRNA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20

4.3 Compensation for Growth

  • MRNA's earnings are expected to grow with 13.46% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y11.1%
EPS Next 3Y13.46%

More info and screens

0

5. Dividend

5.1 Amount

  • MRNA does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

MODERNA INC

NASDAQ:MRNA (1/16/2026, 8:00:01 PM)

After market: 41.82 -0.01 (-0.02%)

41.83

+2.47 (+6.28%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06
Earnings (Next)02-12
Inst Owners71.72%
Inst Owner Change-0.01%
Ins Owners2.73%
Ins Owner Change1.52%
Market Cap16.34B
Revenue(TTM)2.23B
Net Income(TTM)-3.12B
Analysts56
Price Target37.59 (-10.14%)
Short Float %19.22%
Short Ratio6.33
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)52.94%
Min EPS beat(2)29.6%
Max EPS beat(2)76.27%
EPS beat(4)3
Avg EPS beat(4)30.21%
Min EPS beat(4)-6.26%
Max EPS beat(4)76.27%
EPS beat(8)7
Avg EPS beat(8)49.68%
EPS beat(12)9
Avg EPS beat(12)9.25%
EPS beat(16)12
Avg EPS beat(16)10.78%
Revenue beat(2)2
Avg Revenue beat(2)17.81%
Min Revenue beat(2)12.36%
Max Revenue beat(2)23.26%
Revenue beat(4)3
Avg Revenue beat(4)8.94%
Min Revenue beat(4)-0.3%
Max Revenue beat(4)23.26%
Revenue beat(8)7
Avg Revenue beat(8)29.87%
Revenue beat(12)10
Avg Revenue beat(12)27.21%
Revenue beat(16)13
Avg Revenue beat(16)22.97%
PT rev (1m)-1.25%
PT rev (3m)-20.65%
EPS NQ rev (1m)0.31%
EPS NQ rev (3m)6.6%
EPS NY rev (1m)1.09%
EPS NY rev (3m)17.66%
Revenue NQ rev (1m)0.88%
Revenue NQ rev (3m)-12.85%
Revenue NY rev (1m)0.1%
Revenue NY rev (3m)-1.22%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 7.32
P/FCF N/A
P/OCF N/A
P/B 1.75
P/tB 1.77
EV/EBITDA N/A
EPS(TTM)-8.07
EYN/A
EPS(NY)-7.11
Fwd EYN/A
FCF(TTM)-6.82
FCFYN/A
OCF(TTM)-5.06
OCFYN/A
SpS5.71
BVpS23.88
TBVpS23.63
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -25.68%
ROE -33.4%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 63.49%
FCFM N/A
ROA(3y)-6.14%
ROA(5y)4.17%
ROE(3y)-7.66%
ROE(5y)6.83%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-6.55%
GM growth 5YN/A
F-Score2
Asset Turnover0.18
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 329.33%
Cap/Sales 30.69%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.93
Quick Ratio 3.73
Altman-Z 4.04
F-Score2
WACC8.82%
ROIC/WACCN/A
Cap/Depr(3y)261.63%
Cap/Depr(5y)224.68%
Cap/Sales(3y)14.96%
Cap/Sales(5y)10.95%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-38.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1800%
EPS Next Y11.47%
EPS Next 2Y11.1%
EPS Next 3Y13.46%
EPS Next 5Y16.39%
Revenue 1Y (TTM)-56.07%
Revenue growth 3Y-44.04%
Revenue growth 5Y122.01%
Sales Q2Q%-45.44%
Revenue Next Year-40.97%
Revenue Next 2Y-22.34%
Revenue Next 3Y-11.19%
Revenue Next 5Y10.92%
EBIT growth 1Y-46.28%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year19.1%
EBIT Next 3Y15.77%
EBIT Next 5Y17.94%
FCF growth 1Y-0.23%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y4.81%
OCF growth 3YN/A
OCF growth 5YN/A

MODERNA INC / MRNA FAQ

What is the fundamental rating for MRNA stock?

ChartMill assigns a fundamental rating of 3 / 10 to MRNA.


What is the valuation status for MRNA stock?

ChartMill assigns a valuation rating of 0 / 10 to MODERNA INC (MRNA). This can be considered as Overvalued.


How profitable is MODERNA INC (MRNA) stock?

MODERNA INC (MRNA) has a profitability rating of 2 / 10.